Antibody status at delivery and pregnancy outcomes during the first Danish COVID-19 wave
Danish Medical Journal · 2024
DOI: 10.61409/a10230657 ↗Kurz gefasst
Fachartikel in der Zeitschrift Danish Medical Journal, 2024. Verfasst von Victoria Holten Springborg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Copenhagen University Hospital - North Zealand, Hilleroed. Hauptthemen laut MEDLINE: COVID-19, Pregnancy Complications, Infectious, Pregnancy Outcome, Antibodies, Viral. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION. We aimed to investigate the prevalence of SARS-CoV-2 infection and SARS-CoV-2 antibodies in parturient women and their newborns during the first Danish COVID-19 wave and to identify associations with maternal background characteristics, self-reported symptoms, and pregnancy outcomes. METHODS. In a single-centre, prospective cohort study from Denmark, we invited 1,883 women with singleton pregnancies giving live birth from 25 May 2020 to 2 November 2020. Hereof, 953 (50.6%) women were included. Nasopharyngeal swabs, maternal and umbilical cord blood samples, and questionnaires were collected. Medical records were available for participants and non-participants. RESULTS. SARS-CoV-2 antibodies were found in 1.3% of the women. All newborns of seropositive women had SARS-CoV-2 antibodies in cord blood. No association was found between SARS-CoV-2 antibodies and pregnancy outcomes. Self-reported loss of smell correlated with seropositivity (p < 0.001). No women were hospitalised due to COVID-19 during pregnancy or had a positive nasopharyngeal swab intrapartum. CONCLUSIONS. The prevalence of COVID-19 in pregnancy was low during the first wave. Maternal SARS-CoV-2 antibodies were associated with antibodies in cord blood, loss of smell and positive SARS-CoV-2 swab during pregnancy, but not with any adverse pregnancy outcomes. FUNDING. Ferring Pharmaceuticals funded part of the study. TRIAL REGISTRATION. The study was approved by the Regional Committee on Health Research Ethics (H-20028002) and the Danish Data Protection Agency (P-2020-264).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, Copenhagen University Hospital - North Zealand, Hilleroed.
- Department of Clinical Biochemistry, Copenhagen University Hospital - North Zealand, Hilleroed.
- Department of Clinical Medicine, University of Copenhagen, 4) Department of Clinical Biochemistry.
- Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark.
Zitieren
APA
Springborg, V. H., Milbak, J., Egge, S., Bendix, J. M., Vinterberg, N., Ammitzbøll, I., Jensen, C. A., Axelsson, P. B., Løkkegaard, E. C. L., Rode, L., & Clausen, T. D. (2024). Antibody status at delivery and pregnancy outcomes during the first Danish COVID-19 wave. Danish Medical Journal. https://doi.org/10.61409/a10230657
Vancouver
Springborg VH, Milbak J, Egge S, Bendix JM, Vinterberg N, Ammitzbøll I, et al. Antibody status at delivery and pregnancy outcomes during the first Danish COVID-19 wave. Danish Medical Journal. 2024. doi:10.61409/a10230657
BibTeX
@article{Springborg2024,
author = {Springborg, Victoria Holten and Milbak, Julie and Egge, Sissil and Bendix, Jane Marie and Vinterberg, Nanna and Ammitzbøll, Ida LA and Jensen, Claus Aj and Axelsson, Paul Bryde and Løkkegaard, Ellen Christine Leth and Rode, Line and Clausen, Tine Dalsgaard},
title = {Antibody status at delivery and pregnancy outcomes during the first Danish COVID-19 wave},
journal = {Danish Medical Journal},
year = {2024},
doi = {10.61409/a10230657}
}
EUVIMED